PDF(Pubmed)
Abstract：
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of traditional chemotherapy and chemoimmunotherapy regimens. Multiple studies on new BTK inhibitors are ongoing, which may provide more therapeutic options for the treatment of B-cell malignancies. Considering the unmet need of evidence on BTK inhibitors in all clinical settings and to standardize the use of BTK inhibitors available in mainland China, Taiwan, Hong Kong, and Macau regions, this consensus has been formulated for the treatment of various B-cell malignancies based on the clinical practice and available evidences on the use of BTK inhibitors. The recommendations of this consensus will provide guidance to physicians and clinical researchers on the effective treatment of B-cell malignancies with BTK inhibitors.
摘要：
布鲁顿酪氨酸激酶（BTK）抑制剂的靶向治疗彻底改变了各种B细胞恶性肿瘤患者的治疗方法。BTK抑制剂，如ibrutinib，扎努布替尼,奥列拉布替尼,与传统化疗和化学免疫治疗方案相比,阿卡拉布替尼已显示出良好的临床疗效和更好的安全性.关于新BTK抑制剂的多项研究正在进行中，这可能为B细胞恶性肿瘤的治疗提供更多的治疗选择。考虑到BTK抑制剂在所有临床环境中的证据需求未得到满足，并使BTK抑制剂在中国大陆的使用标准化，台湾,香港,和澳门地区，根据临床实践和使用BTK抑制剂的现有证据,为各种B细胞恶性肿瘤的治疗制定了这一共识.该共识的建议将为医生和临床研究人员提供有关BTK抑制剂有效治疗B细胞恶性肿瘤的指导。
